



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: UMYISACARD (Cycle 2+)

(Page 1 of 4)

A BC Cancer "Compassionate Access Program" request form must be completed and approved prior to treatment.

DOCTOR'S ORDERS		Ht _____ cm	Wt _____ kg	BSA _____ m ²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form				
DATE:	To be given:	Cycle #:		
Date of Previous Cycle: _____				
<p>****<u>Ensure Red Blood Cell Phenotype and Group and Screen</u> for all patients prior to Cycle 1****</p> <p><input type="checkbox"/> Delay treatment _____ week(s)</p> <p><input type="checkbox"/> CBC & Diff day of treatment</p> <p>Proceed with all medications for entire cycle as written, if within 96 hours of Day 1: ANC greater than or equal to 0.5 x 10⁹/L, platelets greater than or equal to 50 x 10⁹/L and serum creatinine/ CrCl as per protocol</p> <p>Dose modification for: <input type="checkbox"/> Hematology: _____ <input type="checkbox"/> Other Toxicity: _____</p> <p>Proceed with treatment based on blood work from _____</p>				
<p>STEROID: (select one)* RN to use patient's therapeutic steroid as pre-med for isatuximab.</p> <p><input type="checkbox"/> PO Only</p> <p style="margin-left: 20px;"><input type="checkbox"/> dexamethasone _____ mg PO once weekly on Days 1, 8, 15, and 22. Take dose 30 minutes prior to isatuximab and on weeks without isatuximab, take dose in the morning</p> <p style="margin-left: 20px;">OR</p> <p style="margin-left: 20px;"><input type="checkbox"/> predniSONE _____ mg PO once weekly on Days 1, 8, 15, and 22. Take dose 30 minutes prior to isatuximab and on weeks without isatuximab, take dose in the morning</p> <p style="margin-left: 20px;">Pharmacy to dispense four doses for Days 1, 8, 15 and 22.</p> <p>OR</p> <p><input type="checkbox"/> PO/IV option</p> <p style="margin-left: 20px;">dexamethasone _____ mg IV in 50 mL NS over 15 minutes given 30 minutes prior to treatment on Days 1, 8 and 15</p> <p style="margin-left: 20px;">AND</p> <p style="margin-left: 20px;">dexamethasone _____ mg PO once weekly on Day 22. Patient to take dose in the morning.</p> <p style="margin-left: 20px;">Pharmacy to dispense one dose for Day 22.</p> <p>OR</p> <p><input type="checkbox"/> No steroid</p> <p>*Refer to Protocol for suggested dosing options</p>				
DOCTOR'S SIGNATURE:		SIGNATURE:		
		UC:		

PROTOCOL CODE: UMYISACARD (Cycle 2+)

(Page 2 of 4)

A BC Cancer "Compassionate Access Program" request form must be completed and approved prior to treatment.

DATE:

ISATUXIMAB

- Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily

ISATUXIMAB PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____.

- If no reaction after 4 consecutive doses of isatuximab, may discontinue acetaminophen, loratadine/diphenhydrAMINE, famotidine and montelukast

30 minutes prior to isatuximab infusion:

dexamethasone PO or **predniSONE** as ordered in steroid section, above

☐ **montelukast 10 mg** PO prior to each isatuximab

acetaminophen 650 mg PO prior to each isatuximab. Repeat **acetaminophen 650 mg** PO every 4 hours when needed if IV infusion exceeds 4 hours

Select one of the following:

☐ **loratadine 10 mg** PO prior to each isatuximab, then **diphenhydrAMINE 50 mg** IV every 4 hours when needed for isatuximab reaction

OR

☐ **diphenhydrAMINE 50 mg** ☐ PO or ☐ IV prior to each isatuximab. Repeat **diphenhydrAMINE 50 mg** IV every 4 hours when needed for isatuximab reaction

Optional (See protocol):

☐ **famotidine 20 mg** IV in NS 100 mL over 15 minutes (Y-site compatible with diphenhydrAMINE, if using)

CARFILZOMIB PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____.

☐ **ondansetron 8 mg** PO prior to carfilzomib

☐ **Other:**
****Have Hypersensitivity Reaction Tray and Protocol Available****

ISATUXIMAB

CYCLE 2 onwards, Days 1 and 15:

isatuximab 10 mg/kg x _____ kg = _____ mg IV in 250 mL NS (use 0.2 micron in-line filter)

Infusion rate for cycle 2 onwards: Physician to determine rate of infusion

If no reaction in the previous infusion or reaction is Grade 2 or less:

☐ Infuse over 30 minutes

OR

If reaction in the previous infusion is Grade 3:

☐ Start at 100 mL/hour. If no infusion-related reactions after 60 minutes, increase by 50 mL/hour every 60 minutes to a maximum rate of 200 mL/hour.

Vital signs immediately before the start, at the end of the infusion and as needed. Vital signs not required after 4 treatments with no reaction.



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: UMYISACARD (Cycle 2+)

(Page 3 of 4)

A BC Cancer "Compassionate Access Program" request form must be completed and approved prior to treatment.

DOCTOR'S SIGNATURE:	SIGNATURE: UC:
DATE:	
Have Hypersensitivity Reaction Tray and Protocol Available	
PREHYDRATION (Optional- see protocol. May be given during isatuximab observation): <input type="checkbox"/> 250 mL NS IV over 30 minutes prior to carfilzomib	
CARFILZOMIB CYCLE 2 onward: carfilzomib 70 mg/m ² x BSA* = _____ mg IV in 100 mL D5W over 30 minutes on Days 1, 8 and 15 *(cap BSA at 2.2 m ²) Vital signs prior to EACH carfilzomib infusion	
DOSE MODIFICATION IF REQUIRED ON DAYS 8 AND/OR 15 carfilzomib 70 mg/m ² x BSA* = _____ mg <input type="checkbox"/> Dose Modification: _____ mg/m ² x BSA* = _____ mg IV in 100 mL D5W over 30 minutes on Days _____	
POST HYDRATION (Optional- see protocol. May be given during carfilzomib observation): <input type="checkbox"/> 250 mL NS IV over 30 minutes after carfilzomib	
OPTIONAL CYCLOPHOSPHAMIDE: <input type="checkbox"/> cyclophosphamide 500 mg PO once weekly in the morning on Days 1, 8, 15 and 22. Dispense _____ cycles. OR <input type="checkbox"/> cyclophosphamide _____ mg PO once weekly in the morning on Days _____. Dispense _____ cycles. OR <input type="checkbox"/> cyclophosphamide 50 mg PO once in the morning every 2 days for 14 doses. Dispense _____ cycles.	



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: UMYISACARD (Cycle 2+)

(Page 4 of 4)

A BC Cancer "Compassionate Access Program" request form must be completed and approved prior to treatment.

DOCTOR'S SIGNATURE:		SIGNATURE:
		UC:
DATE:		
RETURN APPOINTMENT ORDERS		
Book chemo on Days 1, 8, and 15 <input type="checkbox"/> Return in four weeks for Doctor and Cycle _____ <input type="checkbox"/> Return in eight weeks for Doctor and Cycles _____ and _____. Book chemo x 2 cycles. <input type="checkbox"/> Return in twelve weeks for Doctor and Cycles _____, _____ and _____. Book chemo x 3 cycles <input type="checkbox"/> Last Cycle. Return in _____ week(s).		
CBC & Diff, creatinine, urea, sodium, potassium, total bilirubin, ALT, alkaline phosphatase, calcium, albumin, phosphate, random glucose, LDH, serum protein electrophoresis <u>and</u> serum free light chain levels every 4 weeks <input type="checkbox"/> Immunoglobulin panel (IgA, IgG, IgM) every 4 weeks <input type="checkbox"/> Urine protein electrophoresis every 4 weeks <input type="checkbox"/> Beta-2 microglobulin every 4 weeks <input type="checkbox"/> CBC & Diff on Days 8, 15, 22 <input type="checkbox"/> Creatinine, sodium, potassium on Days 8, 15, 22 <input type="checkbox"/> Total bilirubin, ALT, alkaline phosphatase on Days 8, 15, 22 <input type="checkbox"/> Random glucose on Days 8, 15, 22 <input type="checkbox"/> Calcium, albumin on Days 8, 15, 22 <input type="checkbox"/> Phosphate Days 8, 15, 22 <input type="checkbox"/> HBV viral load prior to next cycle <input type="checkbox"/> CBC & Diff, platelets, peripheral smear, LDH, total and direct bilirubin, haptoglobin, DAT, creatinine, urea <input type="checkbox"/> See general orders sheet for additional requests <input type="checkbox"/> Other tests: <input type="checkbox"/> Consults		
DOCTOR'S SIGNATURE:		SIGNATURE:
		UC: